why choose us

First received: October 21, 2024

Clinical Trial: Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Colo-rectal Cancer

Study Type: OBSERVATIONAL


Official Title: An Exosome-Based Liquid Biopsy Assay to Detect Molecular Residual Disease for the Identification of High-Risk Patients With Stage II-III Colorectal Cancer

Brief Summary: This study aims to establish an exosome-based liquid biopsy signature to detect molecular residual disease (MRD) in stage II-III colorectal cancer (CRC) patients.Identifying patients with MRD after surgery is crucial for selecting appropriate candidates for adjuvant chemotherapy (ACT), allowing for more personalized treatment approaches and potentially improving patient outcomes.

Read more